{
    "clinical_study": {
        "@rank": "40156", 
        "arm_group": {
            "arm_group_label": "afatinib + nimotuzumab", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "To find the optimal dose of afatinib and nimotuzumab in patients who acquired resistance to\n      gefitinib or erlotinib."
        }, 
        "brief_title": "Afatinib Plus Nimotuzumb for NSCLC", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "NSCLC", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed diagnosis of stage IIIB or IV NSCLC\n\n          -  Presence of EGFR sensitizing mutations (L858R mutation in exon 21 or exon 19\n             deletion) or response by RECIST on prior gefitinib or erlotinib or stable disease on\n             prior gefitinib or erlotinib for at least 6 months\n\n          -  Disease progression on treatemtn with gefitinib or erlotinib within 30 days\n\n          -  Biopsy on disease progression\n\n          -  Age \u226520 years\n\n          -  ECOG performance status of 0, 1, or 2\n\n          -  Measurable disease by the criteria of RECIST 1.1\n\n          -  Adequate organ function as evidenced by the following; Absolute neutrophil count >\n             1.5 x 109/L; platelets > 100 x 109/L; total bilirubin \u22641.5 UNL; AST and/or ALT < 5\n             UNL; creatinine clearance \u2265 45 mL/min\n\n        Exclusion Criteria:\n\n          -  Known interstitial lung disease\n\n          -  Prior treatment with EGFR targeting antibodies or BIBW 2992\n\n          -  Prior three or more lines of chemotherapy for advanced NSCLC\n\n          -  Significant bowel disease impairing drug absorption\n\n          -  Uncontrolled systemic illness such as DM, CHF, unstable angina, hypertension or\n             arrhythmia\n\n          -  Have symptomatic, untreated, or uncontrolled central nervous system (CNS) metastases.\n             Patients with treated CNS metastases are eligible provided their disease is\n             radiographically stable, asymptomatic, and corticosteroid use has been discontinued\n             for at least 2 weeks prior to the first dose of study drug. Screening of asymptomatic\n             patients without history of CNS metastases is not required."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01861223", 
            "org_study_id": "2012-11-087-007"
        }, 
        "intervention": {
            "arm_group_label": "afatinib + nimotuzumab", 
            "intervention_name": "afatinib (30 or 40mg) + nimotuzumab (100 or 200mg)", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "acquired resistance", 
            "gefitinib", 
            "erlotinib"
        ], 
        "lastchanged_date": "February 23, 2014", 
        "location": {
            "contact": {
                "last_name": "Myung-Ju Ahn"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Samsung Medical Center"
            }, 
            "investigator": {
                "last_name": "Jong-Mu Sun", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase Ib Study of Afatinib Plus Nimotuzumab in Non-small Cell Lung Cancer Patients Who Progressed With Reversible EGFR TKI", 
        "overall_contact": {
            "email": "silkahn@skku.edu", 
            "last_name": "Myung-Ju Ahn", 
            "phone": "822-3410-3459"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To establish maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) for BIBW 2992 and nimotuzumab in patients with acquired resistance to erlotinib or gefitinib", 
            "measure": "Maximal tolerated dose", 
            "safety_issue": "Yes", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01861223"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Samsung Medical Center", 
            "investigator_full_name": "Myung-Ju Ahn", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Samsung Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Samsung Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}